Evidence analysisNovember 14, 2026Health & Science

Analysis of antimicrobial resistance in the LAKANA trial of azithromycin administration in Mali: A sub-study of a cluster randomized clinical trial

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

Evidence Dossier: Azithromycin Mass Administration and Antimicrobial Resistance from the LAKANA Trial in Mali

What is established

Mass drug administration (MDA) of azithromycin has been trialed as a public health intervention to reduce under-five mortality in sub-Saharan Africa, with some studies showing mortality benefit especially when given to children aged 1 to 59 months. However, increased antimicrobial resistance (AMR), particularly macrolide resistance, has been observed in some contexts where azithromycin MDA was implemented. This tension has led to WHO recommending azithromycin MDA be limited to infants aged 1–11 months in high mortality settings, paired with careful AMR monitoring. Previous studies have identified Streptococcus pneumoniae and Escherichia coli as key bacterial species in assessing macrolide resistance related to azithromycin use.

What the source claims

A November 2026 PLOS Medicine article analyzed AMR outcomes within the LAKANA trial, a large cluster-randomized, placebo-controlled trial conducted in Mali. Children aged 1–11 months were randomized by village to receive placebo, twice-yearly azithromycin, or quarterly azithromycin over two years. The trial found no mortality reduction from azithromycin administration in this population.

The sub-study focused on phenotypic resistance in S. pneumoniae (nasopharyngeal samples) and E. coli (rectal samples) isolated from young treated children (4–14 months) and untreated older children (49–59 months) at baseline and at 12-, 24-, and 36-month post-enrollment.

  • At 36 months, the prevalence of macrolide resistance in S. pneumoniae was similar between placebo and twice-yearly azithromycin groups (about 13–14%), with differences well within a predefined noninferiority margin of +10 percentage points, implying no significant increase due to twice-yearly dosing.
  • Quarterly azithromycin showed higher macrolide resistance (around 17% in S. pneumoniae and 9% in E. coli) but confidence intervals could not exclude a modest increase in resistance, leaving some uncertainty on dose-dependent effects.
  • No clear increase in macrolide resistance was observed in untreated older children, suggesting limited spillover of resistant bacteria.
  • Resistance to nonmacrolide antibiotics did not increase consistently in any group.

The authors suggest twice-yearly azithromycin MDA to infants did not increase macrolide resistance in treated or untreated children in this context, but quarterly dosing effects require caution. They recommend continuing AMR surveillance, especially when treating broader age groups or using different dosing regimens.

What may be missing from the usual framing

This trial challenges some common assumptions that azithromycin MDA necessarily drives widespread resistance increase on a population level, at least when limited to infants and restricted dosing. The lack of mortality benefit found contrasts with other trials that reported reduced childhood deaths, raising questions about setting-specific factors influencing efficacy. The restriction of AMR findings primarily to phenotypic resistance in two bacterial species means other bacteria or resistance mechanisms may not have been captured.

Moreover, the study population was limited to infants in villages with certain baseline resistance and social conditions; effects might be different if older children or larger portions of the population are treated, as in some Tanzania, Ethiopia, or Niger trials. The study authors acknowledge the size might have limited detection of small resistance increases under quarterly administration, implying statistical power limitations that may mask subtle but epidemiologically relevant changes.

Additional framing omissions include the broader ecological and health system influences on AMR development, such as antibiotic use outside the trial or local healthcare access and sanitation conditions, which were not discussed in detail. The trial’s focus on a rural Malian context may limit generalizability to other sub-Saharan regions with different bacterial ecology or antibiotic pressures.

Competing evidence or uncertainty

Other studies of azithromycin MDA for childhood mortality, including trials in Niger and Ethiopia, have reported mortality reductions but also associated increased macrolide resistance in S. pneumoniae and other pathogens. This creates a complex picture where beneficial mortality effects may come at the cost of rising AMR, although the magnitude and persistence of resistance vary.

The LAKANA trial’s contrasting null mortality finding raises uncertainty about the consistency of azithromycin efficacy across settings. Reasons may include differences in baseline disease prevalence, local bacterial strains, healthcare infrastructure, or MDA implementation fidelity.

Current scientific consensus considers AMR a significant global health threat, and even modest increases in antibiotic resistance could lead to longer-term negative impacts on treatment options. The LAKANA trial results are a valuable contribution but do not eliminate concerns that broader or more intensive azithromycin MDA programs could foster resistance development.

Why it matters

Childhood mortality remains unacceptably high in sub-Saharan Africa despite global progress, prompting urgent investigations into scalable interventions. Azithromycin MDA has been proposed as one such intervention, with debated trade-offs between mortality benefit and AMR risk. Understanding the balance of benefits and harms informs policy decisions by ministries of health and international organizations like WHO.

This study highlights that dosing frequency and target age groups may critically influence AMR outcomes. Limiting treatment to infants and using twice-yearly dosing might avoid large AMR increases, but quarterly dosing or expanding to older children could carry risks. These nuanced findings underscore the need for cautious, context-specific implementation rather than wholesale adoption of MDA programs.

Ongoing and transparent AMR surveillance integrated into public health interventions is essential to detect emerging resistance patterns early, ensuring the durability of antibiotic effectiveness and safe use of mass treatments.

What to verify next

  • Additional data on molecular resistance mechanisms and other bacterial species beyond S. pneumoniae and E. coli to better characterize AMR emergence.
  • Longer-term follow-up studies to evaluate persistence or reversibility of resistance after cessation of azithromycin MDA.
  • Comparative analyses of mortality benefits versus AMR risks in different epidemiological and healthcare settings.
  • Assessment of potential indirect effects on untreated community members and on horizontal gene transfer between bacterial populations.
  • Evaluation of other contributing factors to resistance, such as concurrent antibiotic use outside MDA or community sanitation improvements.

Readers are encouraged to consult the original PLOS Medicine article for comprehensive details and context: Analysis of antimicrobial resistance in the LAKANA trial of azithromycin administration in Mali, published November 13, 2026.

Source & verification

Primary source: PLOS Medicine · November 13, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EudraGMDP database

What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…